CB
VKTX icon

CNB Bank’s Viking Therapeutics VKTX Stock Holding History

CNB Bank’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Sell
3,097
-963
-24% -$31K 0.04% 204
2025
Q4 		$143K Sell
4,060
-1,696
-29% -$60.1K 0.06% 179
2025
Q3 		$151K Buy
5,756
+279
+5% +$8.32K 0.06% 176
2025
Q2 		$145K Buy
5,477
+147
+3% +$3.87K 0.07% 161
2025
Q1 		$129K Buy
5,330
+3,124
+142% +$98.7K 0.07% 176
2024
Q4 		$88.8K Buy
2,206
+1,433
+185% +$81.7K 0.04% 195
2024
Q3 		$48.9K Buy
+773
New +$45.4K 0.02% 253

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

CNB Bank's VKTX Position: Q1 2026 in Review

CNB Bank reduced its Viking Therapeutics (VKTX) stake by 24% in Q1 2026, selling an estimated $31K and leaving 3,097 shares worth $101K. The position accounts for 0.04% of the portfolio, ranked #204.

CNB Bank first reported a position in VKTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $151K in Q3 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • CNB Bank held 3,097 shares of Viking Therapeutics worth $101K as of Q1 2026.
  • CNB Bank sold 963 Viking Therapeutics shares in Q1 2026, an estimated $31K.
  • Viking Therapeutics made up 0.04% of CNB Bank's portfolio in Q1 2026, its #204 holding.
  • CNB Bank first reported a position in Viking Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • CNB Bank's Viking Therapeutics position peaked at $151K in Q3 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on CNB Bank's 13F filing for Q1 2026, filed 6 May 2026.